Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 32

1.

Iron- and cobalt-catalyzed arylation of azetidines, pyrrolidines, and piperidines with Grignard reagents.

Barré B, Gonnard L, Campagne R, Reymond S, Marin J, Ciapetti P, Brellier M, Guérinot A, Cossy J.

Org Lett. 2014 Dec 5;16(23):6160-3. doi: 10.1021/ol503043r. Epub 2014 Nov 17.

PMID:
25401684
2.

A high-definition view of functional genetic variation from natural yeast genomes.

Bergström A, Simpson JT, Salinas F, Barré B, Parts L, Zia A, Nguyen Ba AN, Moses AM, Louis EJ, Mustonen V, Warringer J, Durbin R, Liti G.

Mol Biol Evol. 2014 Apr;31(4):872-88. doi: 10.1093/molbev/msu037. Epub 2014 Jan 14.

3.

Risk of new or recurrent cancer under immunosuppressive therapy in patients with IBD and previous cancer.

Beaugerie L, Carrat F, Colombel JF, Bouvier AM, Sokol H, Babouri A, Carbonnel F, Laharie D, Faucheron JL, Simon T, de Gramont A, Peyrin-Biroulet L; CESAME Study Group.

Gut. 2014 Sep;63(9):1416-23. doi: 10.1136/gutjnl-2013-305763. Epub 2013 Oct 25.

PMID:
24162591
4.

How should we define STAT3 as an oncogene and as a potential target for therapy?

Sellier H, Rébillard A, Guette C, Barré B, Coqueret O.

JAKSTAT. 2013 Jul 1;2(3):e24716. doi: 10.4161/jkst.24716. Epub 2013 Apr 16. Review.

5.

STAT3 as a new autophagy regulator.

Jonchère B, Bélanger A, Guette C, Barré B, Coqueret O.

JAKSTAT. 2013 Jul 1;2(3):e24353. doi: 10.4161/jkst.24353. Epub 2013 Aug 15.

6.

Circulating miRNAs as new activators of the JAK-STAT3 pathway.

Lam D, Barré B, Guette C, Coqueret O.

JAKSTAT. 2013 Jan 1;2(1):e22996. doi: 10.4161/jkst.22996.

7.

pRb/E2F-1-mediated caspase-dependent induction of Noxa amplifies the apoptotic effects of the Bcl-2/Bcl-xL inhibitor ABT-737.

Bertin-Ciftci J, Barré B, Le Pen J, Maillet L, Couriaud C, Juin P, Braun F.

Cell Death Differ. 2013 May;20(5):755-64. doi: 10.1038/cdd.2013.6. Epub 2013 Feb 22.

8.

IL-26 is overexpressed in rheumatoid arthritis and induces proinflammatory cytokine production and Th17 cell generation.

Corvaisier M, Delneste Y, Jeanvoine H, Preisser L, Blanchard S, Garo E, Hoppe E, Barré B, Audran M, Bouvard B, Saint-André JP, Jeannin P.

PLoS Biol. 2012;10(9):e1001395. doi: 10.1371/journal.pbio.1001395. Epub 2012 Sep 25.

9.

Excess primary intestinal lymphoproliferative disorders in patients with inflammatory bowel disease.

Sokol H, Beaugerie L, Maynadié M, Laharie D, Dupas JL, Flourié B, Lerebours E, Peyrin-Biroulet L, Allez M, Simon T, Carrat F, Brousse N; CESAME Study Group.

Inflamm Bowel Dis. 2012 Nov;18(11):2063-71. doi: 10.1002/ibd.22889. Epub 2012 Jan 23.

PMID:
22271569
10.

A quantitative proteomic approach of the different stages of colorectal cancer establishes OLFM4 as a new nonmetastatic tumor marker.

Besson D, Pavageau AH, Valo I, Bourreau A, Bélanger A, Eymerit-Morin C, Moulière A, Chassevent A, Boisdron-Celle M, Morel A, Solassol J, Campone M, Gamelin E, Barré B, Coqueret O, Guette C.

Mol Cell Proteomics. 2011 Dec;10(12):M111.009712. doi: 10.1074/mcp.M111.009712. Epub 2011 Oct 10.

11.

c-Myc dependent expression of pro-apoptotic Bim renders HER2-overexpressing breast cancer cells dependent on anti-apoptotic Mcl-1.

Campone M, Noël B, Couriaud C, Grau M, Guillemin Y, Gautier F, Gouraud W, Charbonnel C, Campion L, Jézéquel P, Braun F, Barré B, Coqueret O, Barillé-Nion S, Juin P.

Mol Cancer. 2011 Sep 7;10:110. doi: 10.1186/1476-4598-10-110.

12.

The role of RelA (p65) threonine 505 phosphorylation in the regulation of cell growth, survival, and migration.

Msaki A, Sánchez AM, Koh LF, Barré B, Rocha S, Perkins ND, Johnson RF.

Mol Biol Cell. 2011 Sep;22(17):3032-40. doi: 10.1091/mbc.E11-04-0280. Epub 2011 Jul 7.

13.

Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease.

Peyrin-Biroulet L, Khosrotehrani K, Carrat F, Bouvier AM, Chevaux JB, Simon T, Carbonnel F, Colombel JF, Dupas JL, Godeberge P, Hugot JP, Lémann M, Nahon S, Sabaté JM, Tucat G, Beaugerie L; Cesame Study Group.

Gastroenterology. 2011 Nov;141(5):1621-28.e1-5. doi: 10.1053/j.gastro.2011.06.050. Epub 2011 Jun 25.

PMID:
21708105
14.

Escape from p21-mediated oncogene-induced senescence leads to cell dedifferentiation and dependence on anti-apoptotic Bcl-xL and MCL1 proteins.

de Carné Trécesson S, Guillemin Y, Bélanger A, Bernard AC, Preisser L, Ravon E, Gamelin E, Juin P, Barré B, Coqueret O.

J Biol Chem. 2011 Apr 15;286(15):12825-38. doi: 10.1074/jbc.M110.186437. Epub 2011 Feb 3.

15.

Phosphorylation of the p52 NF-κB subunit.

Barré B, Perkins ND.

Cell Cycle. 2010 Dec 15;9(24):4774-5. Epub 2010 Dec 15. No abstract available. Retraction in: Cell Cycle. 2015;14(5):784.

16.

Regulation of activity and function of the p52 NF-κB subunit following DNA damage.

Barré B, Coqueret O, Perkins ND.

Cell Cycle. 2010 Dec 15;9(24):4795-804. Epub 2010 Dec 15. Retraction in: Cell Cycle. 2014;13(14):2312.

17.

Regulation of the Aurora-A gene following topoisomerase I inhibition: implication of the Myc transcription factor.

Courapied S, Cherier J, Vigneron A, Troadec MB, Giraud S, Valo I, Prigent C, Gamelin E, Coqueret O, Barré B.

Mol Cancer. 2010 Aug 3;9:205. doi: 10.1186/1476-4598-9-205.

18.

The cdk5 kinase regulates the STAT3 transcription factor to prevent DNA damage upon topoisomerase I inhibition.

Courapied S, Sellier H, de Carné Trécesson S, Vigneron A, Bernard AC, Gamelin E, Barré B, Coqueret O.

J Biol Chem. 2010 Aug 27;285(35):26765-78. doi: 10.1074/jbc.M109.092304. Epub 2010 Jun 1.

19.
20.

[Transient transformation as a permanent oncogenic loop].

Coqueret O, Barré B.

Med Sci (Paris). 2010 Apr;26(4):339-41. doi: 10.1051/medsci/2010264339. French. No abstract available.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk